Immunic Inc (IMUX)

$12.08 -0.57 (-4.54%)
Market Cap 176.41M
Revenue (ttm) 0.00
Net Income (ttm) -97.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 161,700
Avg Vol 301,163
Day's Range N/A - N/A
Shares Out 13.62M
Stochastic %K 82%
Beta 1.20
Analysts Strong Sell
Price Target $42.71

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
takingstock73
takingstock73 May. 15 at 5:58 PM
$IMUX dunzo ? overall market is a mess , I'd say we are down an expected proportion
1 · Reply
Jw242
Jw242 May. 15 at 4:28 PM
$IMUX low volume destructions by the MMs
0 · Reply
Jw242
Jw242 May. 15 at 3:20 PM
$IMUX dunzo
0 · Reply
Cattitude
Cattitude May. 13 at 7:01 PM
$IMUX anything interesting on the call? 📞
1 · Reply
WeAllFallDown
WeAllFallDown May. 13 at 3:32 PM
$IMUX Ah-damn! Ignored the RS as it is typical behavior of a biopharma run up when they got something of substance...refuse to put out a PT as with so few MS on the market, who knows? Hope for all of the MS victims out there...millions...that they actually have something here...
0 · Reply
Genno
Genno May. 13 at 3:30 PM
$IMUX Raize your feet up and enjoy
1 · Reply
STACKD0E
STACKD0E May. 13 at 3:27 PM
$NVCT $CCCC $IMUX
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 13 at 3:00 PM
$IMUX Q1 '26 Earnings Results & Recap Immunic expects to fund operations into late 2027 with $200M from a private placement, targeting NDA submission in mid-2027 and regulatory approval in 2028 for vidofludimus calcium.
0 · Reply
Luke_Black
Luke_Black May. 13 at 2:39 PM
$IMUX target price?
1 · Reply
Mattjen
Mattjen May. 13 at 1:19 PM
$IMUX is a credible late-stage MS commercial candidate....
0 · Reply
Latest News on IMUX
Immunic price target lowered to $19 from $26 at Roth Capital

2026-05-14T14:51:40.000Z - 1 day ago

Immunic price target lowered to $19 from $26 at Roth Capital

Immunic reports Q1 EPS ($1.08), consensus (96c)

2026-05-13T11:25:48.000Z - 2 days ago

Immunic reports Q1 EPS ($1.08), consensus (96c)

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 6:30 AM EDT - 2 days ago

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic initiated with an Outperform at LifeSci Capital

2026-05-04T11:36:42.000Z - 11 days ago

Immunic initiated with an Outperform at LifeSci Capital

Immunic to Participate in Investor and Medical Conferences in May

Apr 30, 2026, 6:30 AM EDT - 15 days ago

Immunic to Participate in Investor and Medical Conferences in May

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

2026-04-30T10:14:29.000Z - 15 days ago

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed

2026-04-28T11:19:28.000Z - 17 days ago

Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Apr 28, 2026, 6:30 AM EDT - 17 days ago

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic trading halted, news pending

2026-04-24T23:52:54.000Z - 21 days ago

Immunic trading halted, news pending

Immunic announces 1-for-10 reverse stock split

2026-04-23T12:08:47.000Z - 22 days ago

Immunic announces 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Apr 23, 2026, 8:00 AM EDT - 22 days ago

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic initiated with a Buy at Stifel

2026-04-16T20:20:56.000Z - 4 weeks ago

Immunic initiated with a Buy at Stifel

Immunic downgraded to Hold from Buy at D. Boral Capital

2026-04-15T11:24:13.000Z - 4 weeks ago

Immunic downgraded to Hold from Buy at D. Boral Capital

Immunic to Participate in Scientific and Medical Conferences in April

Apr 9, 2026, 6:30 AM EDT - 5 weeks ago

Immunic to Participate in Scientific and Medical Conferences in April

Immunic files to sell 458.15M shares of common stock for holders

2026-04-02T20:35:15.000Z - 6 weeks ago

Immunic files to sell 458.15M shares of common stock for holders

Immunic regains compliance with Nasdaq

2026-04-01T10:40:28.000Z - 6 weeks ago

Immunic regains compliance with Nasdaq

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 1, 2026, 6:30 AM EDT - 6 weeks ago

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

2026-03-31T11:08:33.000Z - 6 weeks ago

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

MLYS

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Mar 31, 2026, 6:30 AM EDT - 6 weeks ago

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Immunic initiated with a Buy at Guggenheim

2026-03-24T09:10:20.000Z - 7 weeks ago

Immunic initiated with a Buy at Guggenheim

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 12:00 PM EDT - 2 months ago

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Immunic Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:40 AM EDT - 2 months ago

Immunic Transcript: Leerink Global Healthcare Conference 2026

Immunic gets European patent for vidofludimus calcium

2026-03-10T10:45:47.000Z - 2 months ago

Immunic gets European patent for vidofludimus calcium

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 10, 2026, 6:30 AM EDT - 2 months ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Immunic to Participate in Investor Conferences in March

Mar 3, 2026, 6:30 AM EST - 2 months ago

Immunic to Participate in Investor Conferences in March

Immunic price target lowered to $5 from $8 at H.C. Wainwright

2026-03-02T11:27:48.000Z - 2 months ago

Immunic price target lowered to $5 from $8 at H.C. Wainwright

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:30 AM EST - 2 months ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 17, 2026, 4:05 PM EST - 3 months ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 13, 2026, 6:30 AM EST - 3 months ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Feb 4, 2026, 6:30 AM EST - 3 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Jan 7, 2026, 6:30 AM EST - 4 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 9:35 AM EST - 5 months ago

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 26, 2025, 6:30 AM EST - 6 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:30 AM EST - 6 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Oct 29, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

Oct 1, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 25, 2025, 6:30 AM EDT - 8 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 8 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Immunic to Participate in Investor and Scientific Conferences in September

Sep 4, 2025, 6:30 AM EDT - 9 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 10 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 11 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 1 year ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 1 year ago

Immunic, Inc. Announces Proposed Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Transcript: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Transcript: Study Update

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 1:20 PM EST - 1 year ago

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 11:30 AM EST - 1 year ago

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings Call Transcript: Q3 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 3:05 PM EDT - 1 year ago

Immunic Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Immunic Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Immunic Earnings Call Transcript: Q2 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

takingstock73
takingstock73 May. 15 at 5:58 PM
$IMUX dunzo ? overall market is a mess , I'd say we are down an expected proportion
1 · Reply
Jw242
Jw242 May. 15 at 4:28 PM
$IMUX low volume destructions by the MMs
0 · Reply
Jw242
Jw242 May. 15 at 3:20 PM
$IMUX dunzo
0 · Reply
Cattitude
Cattitude May. 13 at 7:01 PM
$IMUX anything interesting on the call? 📞
1 · Reply
WeAllFallDown
WeAllFallDown May. 13 at 3:32 PM
$IMUX Ah-damn! Ignored the RS as it is typical behavior of a biopharma run up when they got something of substance...refuse to put out a PT as with so few MS on the market, who knows? Hope for all of the MS victims out there...millions...that they actually have something here...
0 · Reply
Genno
Genno May. 13 at 3:30 PM
$IMUX Raize your feet up and enjoy
1 · Reply
STACKD0E
STACKD0E May. 13 at 3:27 PM
$NVCT $CCCC $IMUX
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 13 at 3:00 PM
$IMUX Q1 '26 Earnings Results & Recap Immunic expects to fund operations into late 2027 with $200M from a private placement, targeting NDA submission in mid-2027 and regulatory approval in 2028 for vidofludimus calcium.
0 · Reply
Luke_Black
Luke_Black May. 13 at 2:39 PM
$IMUX target price?
1 · Reply
Mattjen
Mattjen May. 13 at 1:19 PM
$IMUX is a credible late-stage MS commercial candidate....
0 · Reply
Mattjen
Mattjen May. 13 at 12:33 PM
$IMUX
0 · Reply
Stock_AHA
Stock_AHA May. 13 at 11:42 AM
$IMUX Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update Cash and Cash Equivalents as of March 31, 2026 were $186.6 million. With these funds, Immunic expects to be able to fund its operations into late 2027
0 · Reply
Jw242
Jw242 May. 13 at 11:24 AM
$IMUX Epic earnings 😁
2 · Reply
threeputt213
threeputt213 May. 12 at 2:39 PM
$IMUX next catalyst?
0 · Reply
Cnugent123
Cnugent123 May. 12 at 1:16 PM
$IMUX Requesting a status update on this prophecy.
2 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 11:09 AM
$BTAI $CNS $ANVS $VTVT $IMUX
0 · Reply
Stock_AHA
Stock_AHA May. 11 at 8:02 PM
$IMUX $12 A good close… here we go
1 · Reply
Stock_AHA
Stock_AHA May. 11 at 3:06 PM
$IMUX Is it testing the $12 level, or is it just baiting us into buying so they can dump on us?
0 · Reply
michele1twits
michele1twits May. 11 at 12:58 PM
$IMUX lets go
0 · Reply
obedsmartrader
obedsmartrader May. 9 at 7:51 PM
$DOGE.X $IMUX
0 · Reply
Cattitude
Cattitude May. 8 at 10:28 PM
$IMUX I know what I hold, regardless of warrant’s , this is a game changer in the field of ms. This is a solid , life changer for patients and investors, get on the bus or get left behind, simple as that. You’ve been warned!
0 · Reply
emin1903
emin1903 May. 8 at 8:24 PM
$IMUX imux showed good performance overall this week. I anticipate the upward price trend and strengthening to continue.
1 · Reply